PV-267, A Unique Compound Intended to Redirect the Abnormal Immune Response In Multiple Sclerosis
Posted Nov 17 2009 10:20pm
Fast Forward, LLC and ProvidPharmaceuticals Announce Partnership for Development of PV-267, A Unique Compound Intended to Redirect the Abnormal Immune Response In Multiple Sclerosis
New York, USA and North Brunswick, NJ, May 5, 2009 – Provid Pharmaceuticals, Inc, a drug discovery company, and Fast Forward, LLC, the National Multiple Sclerosis Society’s subsidiary devoted to bridging the gap between research and drug development, today announced a partnership to support Provid’s preclinical studies of PV-267. This novel compound is designed to redirect the abnormal immune response associated with multiple sclerosis (MS).